Japanese Pharmas Investing Heavily in Emerging Markets - BioJapan Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
By 2030 the total pharma market size of BRIC countries, together with Mexico and Turkey, could reach $330 billion to $420 billion - almost equal to the combined market size of North America and Japan in 2006, which was $354 billion..
You may also be interested in...
Daiichi Sankyo, Ranbaxy To Start Joint Marketing In Mexico, Romania
TOKYO - Dust from their merger settled, Daiichi Sankyo and generics manufacturing Indian subsidiary Ranbaxy are flexing their muscles, readying to start marketing brand and generic pharmaceuticals in Mexico and launching the postmenopausal osteoporosis drug Evista in Romania
Astellas Opens Brazilian Sales Affiliate, Completing Network In BRIC Countries
TOKYO - Astellas Pharma has opened its first Brazilian beachhead, completing the expansion of its distribution network in the BRIC countries of Brazil, Russia, India and China, a company spokeswoman said July 22. Other Japanese pharmas, including Takeda, are gearing up to follow its lead
As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
MUMBAI - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of the company's management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon